FDA Expedites Review for Endometrial Cancer Combination Therapy

The FDA has granted Fast Track designation to a combination of sapanisertib and serabelisib with paclitaxel for advanced endometrial cancer with PI3K/AKT/mTOR pathway alterations. This designation aims to accelerate the development and review process for therapies addressing serious conditions with unmet medical needs, potentially bringing a new treatment to patients sooner.